Pacira BioSciences, Inc.
PCRX
$27.00
-$0.14-0.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 187.25M | 168.57M | 178.02M | 167.12M | 181.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 187.25M | 168.57M | 178.02M | 167.12M | 181.24M |
| Cost of Revenue | 63.78M | 57.97M | 46.19M | 65.65M | 67.16M |
| Gross Profit | 123.47M | 110.61M | 131.84M | 101.46M | 114.09M |
| SG&A Expenses | 79.61M | 74.33M | 68.13M | 72.03M | 65.80M |
| Depreciation & Amortization | 14.32M | 14.32M | 14.32M | 14.32M | 14.32M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 157.72M | 146.62M | 147.05M | 152.00M | 147.28M |
| Operating Income | 29.53M | 21.95M | 30.98M | 15.12M | 33.97M |
| Income Before Tax | 25.53M | -138.86M | 36.58M | 13.64M | 33.72M |
| Income Tax Expenses | 9.49M | 4.61M | 17.70M | 4.66M | 8.85M |
| Earnings from Continuing Operations | 16.04M | -143.47M | 18.89M | 8.98M | 24.87M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.04M | -143.47M | 18.89M | 8.98M | 24.87M |
| EBIT | 29.53M | 21.95M | 30.98M | 15.12M | 33.97M |
| EBITDA | 50.78M | 42.20M | 49.84M | 33.54M | 52.45M |
| EPS Basic | 0.35 | -3.11 | 0.41 | 0.19 | 0.54 |
| Normalized Basic EPS | 0.41 | 0.31 | 0.43 | 0.21 | 0.46 |
| EPS Diluted | 0.33 | -3.11 | 0.39 | 0.19 | 0.54 |
| Normalized Diluted EPS | 0.39 | 0.31 | 0.39 | 0.19 | 0.41 |
| Average Basic Shares Outstanding | 46.17M | 46.13M | 46.17M | 46.50M | 46.44M |
| Average Diluted Shares Outstanding | 49.04M | 46.13M | 50.54M | 52.19M | 52.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |